Table 2 Demographic and clinical characteristics of SSc patients
From: Evidence of telomere attrition and a potential role for DNA damage in systemic sclerosis
Variables | SSc population (n = 174) |
|---|---|
Age (median, IQR) | 54 (21) |
Gender, female, n (%) | 151 (86.8) |
Race, Caucasian, n (%) | 169 (97.1) |
Smoking history, n (%) | 74 (42.5) |
Comorbidities, n (%) | |
Diabetes mellitus | 15 (8.6) |
Hypertension | 42 (24.1) |
Dyslipidemia | 40 (23.0) |
MACE | 11 (6.3) |
Cancer | 14 (8.1) |
Disease duration1 median (IQR), years | 7 (10) |
Disease subtype, n (%) | |
lcSSc | 105 (60.3) |
dcSSc | 69 (39.6) |
Autoantibodies, n (%) | |
ATA | 54 (31.0) |
ACA | 62 (35.6) |
Clinical involvement of SSc, n (%) | |
Pulmonary hypertension | 17 (9.8) |
Pulmonary (ILD) | 57 (32.7) |
Cardiac | 29 (16.7) |
Gastrointestinal | 137 (78.7) |
Renal | 7 (4.0) |
Previous Therapy, n (%) | |
Glucocorticoids | 98 (56.3) |
Immunosuppressive drugs2 | 80 (46.0) |
Maximal mRSS ever, median (IQR), range 0–51 | 10 (19) |
Death by any cause, n (%) | 34 (19.5) |